Speaker Bios for the Cancer Genomics and the Impact of Next Generation Sequencing Symposium
Mark S. Boguski, MD, PhD
Center for Biomedical Informatics
Harvard Medical School
Department of Pathology
Beth Israel Deaconess Medical Center
About Mark S. Boguski, MD, PhD
Dr. Boguski is on the faculty of Harvard Medical School, Center for Biomedical Informatics, and the Department of Pathology at Beth Israel Deaconess Medical Center in Boston. He has previously held positions at the Johns Hopkins University School of Medicine, the U.S. National Institutes of Health and National Library of Medicine and as an executive in the biotechnology and pharmaceutical industries. Dr. Boguski was the Founding Director of the Allen Institute for Brain Science / Allen Brain Atlas and is a former vice president of the Novartis Institutes for Biomedical Research. He was honored as a Visionary and Influencer by the Personalized Medicine Coalition in 2006. Dr. Boguski was elected to the Institute of Medicine of the U.S. National Academy of Sciences and the American College of Medical Informatics in 2001. He is a Fellow of the College of American Pathologists and a graduate of the Medical Scientist Training Program at Washington University in St. Louis.
M. Eileen Dolan, PhD
Department of Medicine Section of Hematology/Oncology
University of Chicago Knapp Center for BioMedical Discovery
About M. Eileen Dolan, PhD
Dr. M. Eileen Dolan obtained her PhD in Medicinal Chemistry from Purdue University and did a post-doctoral fellowship at Penn State University. Her first faculty position was at the University of Chicago where she is now a tenured Professor of Medicine. She is Chair of the Committee on Clinical Pharmacology and Pharmacogenomics, a board-certified training program for clinical and post-doctoral fellows. Since 2000, she has been co-director of the University of Chicago Comprehensive Cancer Center's Clinical and Experimental Therapeutics Program. Dr. Dolan also teaches pharmacogenomics courses and trains clinical and post-doctoral fellows, graduate students and undergraduates. She is considered a leader in developing cell-based methods to identify genetic variants contributing to chemotherapeutic induced cytotoxicity. She received the Purdue University School of Pharmacy Distinguished Alumni Award, University of Dayton Distinguished Alumni Award and ACS, IL Presidential Award for Volunteer Contributions to Research. She has over 200 publications in the area of chemotherapeutic pharmacology and pharmacogenomics. She has served on study section for NIH, Department of Defense, Cancer Research-UK as well as other national and international organizations. She has multiple NIH grants, is PI of an RO1, PI of a project within the University of Chicago Breast Cancer SPORE, and co-PI of the Pharmacogenetics of Anticancer Agents Research (PAAR) Group, which recently received $10.3 million over 5 years from the NIH and aims to improve the efficacy of anticancer drugs by deciphering the impact of genetic variation on drug response and toxicity.
Peter W. Laird, PhD
Associate Professor; Director, USC Epigenome Center; Vice Chair of Research for the Department of Surgery; Program Leader, Epigenetics and Regulation, Norris Comprehensive Cancer Center; Departments of Surgery and of Biochemistry and Molecular Biology; University of Southern California, Keck School of Medicine; Norris Comprehensive Cancer Center, USC Epigenome Center
About Peter W. Laird, PhD
Dr. Peter W. Laird earned his BS and his MS, Cum Laude, from the University of Leiden, The Netherlands. He received his PhD from the University of Amsterdam with Dr. Piet Borst, Netherlands Cancer Institute, and postdoctoral training with Dr. Anton Berns, Netherlands Cancer Institute, and with Dr. Rudolf Jaenisch, at the Whitehead Institute for Biomedical Research in Cambridge, Massachusetts. In 1996, he joined the faculty of the University of Southern California at the Norris Comprehensive Cancer Center. In 1996, he received the Lily Opas Research Career Development Award from Stop Cancer, and in 1997 a Career Development Award from the USC Liver Disease Research Center. In 1997, he became Director of Basic Research for the Department of Surgery at USC. He was granted tenure in 2002 and appointed head of the Epigenetics and Regulation Program for the Norris Cancer Center in 2004 and Founding Director of the USC Epigenome Center in 2007. Dr. Laird published the first demonstration of a causal role for DNA methylation in oncogenesis (Laird et al., Cell 81, 197,1995). This work was cited as a "milestone" in cancer by Nature magazine (Nature Cancer Milestones, April, 2006). He invented several DNA methylation analysis techniques, including COBRA and MethyLight. He is a member of one of the five AACR Stand Up To Cancer "Dream Teams", and is Principal Investigator of an NIH grant for all epigenomic data production for the next phase of the NCI-funded Cancer Genome Atlas (TCGA).
Adrian V. Lee, PhD
Department of Pharmacology and Chemical Biology
Director, Womens Cancer Research Center
University of Pittsburgh Cancer Institute
Magee-Womens Research Institute
About Adrian V. Lee, PhD
Dr. Adrian V. Lee received his BSc in Biochemistry (1989) from Kent University in England. He performed his graduate studies with Dr Roger J.B. King, PhD, DSc at the Imperial Cancer Research Fund in London, and then at the University of Surrey in Guildford, England (1993). Dr. Lee came to the University of Texas Health Science Center at San Antonio (UTHSCSA) for his postdoctoral studies with Dr Douglas Yee, MD studying the role of IGFs in breast cancer and mechanisms of therapeutic targeting this pathway (1993-1997). He was promoted to Instructor of Medicine (1997-1999) and subsequently recruited as an Assistant Professor to Baylor College of Medicine (1999) where he rose to the position of tenured Associate Professor in the Breast Center and Departments of Medicine and Molecular and Cellular Biology. Dr Lee is currently Visiting Professor of Pharmacology and Chemical Biology at the University of Pittsburgh Cancer Institute and is Director of the Women's Cancer Research Center.
The goal of Dr. Lee's laboratory is to translate basic cell and molecular research findings into the understanding and treatment of breast cancer. To this end, Dr Lee's laboratory studies many aspects of translational breast cancer research utilizing basic biochemistry and molecular biology, cell lines, mouse models and patient biopsies from clinical trials. The main focus of the laboratory is the understanding of how IGFs regulated breast transformation, and how this knowledge can be used for successful treatment of patients. Dr. Lee's lab also studies the role of novel nanotechnology agents in the imaging and treatment of early breast cancer, and fundamental studies on the role of structural genomic rearrangements in breast cancer.
Dr Lee has published over 100 peer reviewed research articles and has funding from NIH, Department of Defense, Susan G. Komen Foundation, and other sources. Dr Lee is a member of the NIH Molecular Oncogenesis (MONC) study section and serves on numerous other national peer-review committees. Dr. Lee has received numerous awards including a T.T. Chao scholarship. Dr. Lee is actively involved in teaching both graduate and medical students and recently developed an elective course titled "Introduction to Leadership Skills".
Victor E. Velculescu, MD, PhD
Associate Professor of Oncology
Director of Cancer Genetics
Ludwig Center at Johns Hopkins
Codirector of Cancer Biology
Johns Hopkins Kimmel Cancer Center at Jefferson
About Victor E. Velculescu, MD, PhD
Dr. Velculescu is internationally known for his genomic discoveries in human cancer. He developed SAGE (serial analysis of gene expression), a gene expression technology that allows for global and quantitative measurement of gene activity. He applied this approach to provide the first insights into gene expression patterns in eukaryotic cells and to identify dysregulated gene expression patterns in human cancer. These studies allowed Dr. Velculescu to coin the word "transcriptome" to describe the comprehensive gene expression patterns that could now be analyzed in human cancer and other cells. This approach provides the basis for new next generation transcript sequencing methods used for genome-wide expression analyses.
Over the past decade, Dr. Velculescu has devised technologies for characterizing the cancer genome. These have included development of Digital Karyotyping, which allows for quantitative characterization of amplifications and deletions at the the DNA level in an unbiased manner. He used this approach to identify copy number alterations that underlie chemotherapy-resistant metastatic colorectal cancer. In parallel, he has developed methods for large-scale sequencing of cancer genomes. Through these approaches his group identified alterations in the PIK3CA gene in a high fraction of colorectal, breast, brain, and other tumors, making this gene one of the most highly mutated cancer genes ever found. He and his colleagues have extended these studies to permit the first sequence analysis of the coding genome in breast, colorectal, brain and pancreatic cancers. Most recently, he has developed PARE (personalized analysis of rearranged ends) for personalized development of genomic biomarkers for tumor detection and monitoring. These discoveries provide insights into the mechanistic features and pathways underlying human cancer and provide new opportunities for individualized diagnostic and therapeutic approaches.
Dr. Velculescu attended Stanford University where he graduated with Honors and Distinction in Biological Sciences in 1992. He obtained his M.D. and Ph.D. in Human Genetics and Molecular Biology in 1999 from the Johns Hopkins University School of Medicine, where he also completed his postdoctoral fellowship in Oncology. He became an Assistant Professor of Oncology in 2002 and an Associate Professor of Oncology in 2006. He is currently Co-Director of the Program in Cancer Biology at the Johns Hopkins University Kimmel Cancer Center and Director of Cancer Genetics at The Ludwig Center for Cancer Genetics and Therapeutics.
Dr. Velculescu is the recipient of multiple honors and awards for his work including the AACR Award for Outstanding Achievement in Cancer Research (2009), the EACR Carcinogenesis Young Investigator Award (2008), The Judson Daland Prize of the American Philosophical Society (2007), The Sir William Osler Young Investigator Award (2006), The Pew Scholar Award (2004), the Order of Merit from the President of Romania (2000), the Grand Prize Winner of the Amersham/Pharmacia & Science Young Scientist Prize (1999), and was one of Popular Science's "Brilliant 10" Young Scientists in 2003. He has given numerous invited lectures and has organized international conferences on topics related to his work.
Richard K. Wilson, PhD
Director, The Genome Center
Washington University in St. Louis
About Richard K. Wilson, PhD
Dr. Wilson is an expert in molecular genetics and large-scale DNA sequence analysis, and his laboratory at the Washington University School of Medicine is among the world's leaders in genome analysis. They have sequenced and analyzed billions of bases of DNA from the genomes of bacteria, yeast, roundworms, plants, vertebrates, primates and humans. Dr. Wilson and his colleagues at The Genome Center sequenced the first animal genome - that of the roundworm Caenorhabditis elegans - and contributed substantially to the sequencing and analysis of the human genome. More recently, Dr. Wilson's laboratory was the first to sequence the genome of a cancer patient and discover genetic signatures relevant to the pathogenesis of the disease. Building upon this achievement, their current focus is to utilize genome sequencing and analysis technology to discover clues that will facilitate more effective diagnosis and treatment of cancer and other human diseases.